ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
· financialpost.com
Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company’s Phase 1b trial of PMN310 in patients with early Alzheimer’s…
Article content
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigatio...